Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025

3.1 Dosage, Patent & Price Analysis – Branded v/s Biosimilar
3.1.1 Avastin
3.1.2 Mvasi
3.1.3 Zirabev
3.1.4 Aybintio
3.2 Avastin - Sales Analysis

4.1 Current Market Scenario
4.2 Market Opportunities & Forecast

5.1 Country
5.2 Indication
5.3 Patient Segment
5.4 Organization

6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-II
6.7 Phase-II/III
6.8 Phase-III
6.9 Preregistration
6.10 Registered

7.1 Avastin
7.2 Bevacizumab Biosimilar - KRABEVA
7.3 Bevacizumab Biosimilar - BYVASDA
7.4 Bevacizumab Biosimilar - Bevax
7.5 Bevacizumab Biosimilar - ZIRABEV
7.6 Bevacizumab Biosimilar - Mvasi
7.7 Bevacizumab Biosimilar - Bryxta
7.8 Bevacizumab Biosimilar Bevatas
7.9 Bevacizumab Biosimilar - Cizumab
7.10 Bevacizumab Biosimilar - Versavo
7.11 Bevacizumab Biosimilar - Lumiere

9.1 Amgen
9.2 AryoGen Pharmed
9.3 Biothera
9.4 Boehringer Ingelheim
9.5 Centus Biotherapeutics
9.6 Henlius Biotech
9.7 Innovent Biologics
9.8 Mylan
9.9 mAbxience
9.10 Outlook Therapeutics
9.11 Pfizer
9.12 Prestige Biopharma
9.13 Roche
9.14 Samsung Bio
9.15 TOT Biopharm

Figure 1-1: Global – Bevacizumab Market Size (US$ Billion), 2017 - 2019
Figure 1-2: Global – Bevacizumab Market Opportunity (US$ Billion), 2020 - 2025
Figure 1-3: Bevecezumab – Market Size by Region (%), 2019
Figure 1-4: Bevecezumab – Market Size by Type of Product (%), 2019
Figure 2-1: US – Average Selling Price (ASP) of Bevacizumab Products (US$/10mg), 2020
Figure 2-2: US – Reimbursed Amount of Bevacizumab Products (US$/10mg), 2020
Figure 3-1: Avastin – FDA Approval Year by Indication
Figure 3-2: Avastin – Patent Expiration Year by Region
Figure 3-3: Avastin – Price for a Supply of 4ml & Price per Unit ml Solution for Injection (US$), December’2020
Figure 3-4: Avastin – Price for a Supply of 16ml & Price per Unit ml Solution for Injection (US$), December’2020
Figure 3-5: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), December’2020
Figure 3-6: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), December’2020
Figure 3-7: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), December’2020
Figure 3-8: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), December’2020
Figure 3-9: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), December’2020
Figure 3-10: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), December’2020
Figure 3-11: Avastin’s Biosimilar - FDA Approval Year
Figure 3-12: Avastin’s Biosimilar - EMA Approval Year
Figure 3-13: Mvasi - Price for 4ml Supply & Price per ml of Intravenous Solution (US$), December’2020
Figure 3-14: Mvasi - Price for 16 ml Supply & Price per Unit of Intravenous Solution (US$), December’2020
Figure 3-15: Zirabev - Price for 4ml Supply & Price per unit of Intravenous Solution (US$), December’2020
Figure 3-16: Zirabev - Price for 16 ml Supply & Price per unit of Intravenous Solution (US$), December’2020
Figure 3-17: Aybintio - Price for 4ml Supply & Price per Unit of Intravenous Solution (GBP/US$), December’2020
Figure 3-18: Aybintio - Price for 16 ml Supply & Price per unit of Intravenous Solution (GBP/US$), December’2020
Figure 3-19: Bevaczumab - Price Comparision for Single Supply of 4 ml Intravenous Solution (US$), December’2020
Figure 3-20: Bevaczumab - Price Comparision for Single Supply of 16 ml Intravenous Solution (US$), December’2020
Figure 3-21: Avastin – Annual Sales Value (US$/CHF Billion), 2017 - 2019
Figure 3-22: Global – Avastin Quarterly Sales Value (US$ Billion), 2018 & 2019
Figure 3-23: US - Avastin Quarterly Sales Value (US$ Million), 2019
Figure 3-24: Avastin – Annual Sales Share by Region (US$ Billion), 2019
Figure 3-25: Avastin – Sales Share by Region (%), 2019
Figure 3-26: Global - Avastin Quarterly Sales Value (US$ Million), Q1 – Q3, 2020
Figure 3-27: Avastin – Sales Share by Region (US$ Billion), Q1 – Q3, 2020
Figure 3-28: Avastin – Sales Share by Region (%), 2019
Figure 4-1: Global – Bevacizumab Biosimilar Market Size by Product (US$ Million), 2019
Figure 4-2: Investigational Bevacizumab Biosimilars & Their Manufacturer
Figure 4-3: Global – Zirabev Market Opportunity (US$ Million), 2019 – 2026
Figure 4-4: Global – Mvasi Market Opportunity (US$ Million), 2019 – 2025
Figure 4-5: US – Mvasi Market Opportunity (US$ Million), 2019 – 2025
Figure 4-6: Global – Bevacizumab Biosimilar Market Opportunity (US$ Billion), 2020 – 2025
Figure 5-1: Global – Bevacizumab Biosimilar Clinical Trials by Country, 2020 – 2025
Figure 5-2: Global – Bevacizumab Biosimilar Clinical Trials by Indication, 2020 – 2025
Figure 5-3: Global – Bevacizumab Biosimilar Clinical Trials by Patient Segment, 2020 – 2025
Figure 5-4: Global – Bevacizumab Biosimilar Clinical Trials by Organization, 2020 – 2025
Figure 6-1: Global – Bevacizumab Biosimilar Clinical Trials by Phase, 2020 – 2025
Figure 6-2: Global – Bevacizumab Biosimilar Clinical Trials by Phase, 2020 – 2025